Novel molecular targets in pain control

Current Opinion in Anaesthesiology

Volumn 16, Issue 5, 2003, Pages 521-525

  Dray, Andy ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Analgesia; Enzymes; GPCRs; Ion channels; Pain

Indexed keywords

1 [3 (10,11 DIHYDRO 5H DIBENZO[A,D]CYCLOHEPTEN 5 YLIDENE)PROPYL] 3 PIPERIDINECARBOXYLIC ACID; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; A 317491; ANANDAMIDE; ANTIHISTAMINIC AGENT; CANNABINOID; CANNABINOID RECEPTOR; CHLORPHENIRAMINE; DD 161515; DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR AGONIST; DIZOCILPINE; ENZYME; GLUTAMATE RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; HISTAMINE H1 RECEPTOR ANTAGONIST; ION CHANNEL; KAPPA OPIATE RECEPTOR; MEPYRAMINE; METABOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR ANTAGONIST; MORPHINE; MU OPIATE RECEPTOR; NEUROTROPHIN; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; PURINE ANTAGONIST; PURINE P2X RECEPTOR ANTAGONIST; RECEPTOR; RECEPTOR BLOCKING AGENT; REGULATOR PROTEIN; SODIUM CHANNEL; SURAMIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANILLOID RECEPTOR ANTAGONIST;

ANALGESIA; CATALEPSY; CHRONIC PAIN; CLINICAL STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; GLIA; HUMAN; HYPERACTIVITY; LOW DRUG DOSE; MOTOR DYSFUNCTION; PHOSPHORYLATION; PRIORITY JOURNAL; REVIEW; SENSORY NERVE CELL; TIME;

EID: 0142061618     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001503-200310000-00013     Document Type: Review

References (19)

1. Salter MW. The neurobiology of central sensitization. J Musculoskelet Pain 2002; 10:23-33. A clear overview of the multipticity of mechanisms and molecular targets involved in the plastic changes occurring in pain conditions.
2. Malan TP, Ibrahim MM, Lai J, et al. CB2 cannabinoid receptor agonists: pain relief without psychoactive effects? Curr Opin Pharmacol 2003; 3:62-67. Good overview of the evidence for CB2 involvement in chronic pain conditions.
3. Cichewicz DL, McCarthy EA. Antinociceptive synergy between Δ9 tetrahydrocannabinol and opioids after oral administration. J Pharmacol Exp Ther 2003; 304:1010-1015.
4. Olsen U, Christinat E, Bentek I, et al. ReN 1869, a novel tricyclic antihistamine, is active against neurogenic pain and inflammation. Eur J Pharmacol 2002; 435:43-57.
5. Hudson LJ, Sevan S, McNair K, et al. Metabotropic glutamate receptor 5 upregulation in A-fibers after spinal nerve injury: 2-methyl-6-(phenylethynyl)- pyridine (MPEP) reverses the induced thermal hyperalgesia. J Neurosci 2002; 22:2660-2668.
6. Jarvis MF, Burgard EC, McGaraughty S, et al. A-317491, a novel potent and selective nonnucleotide antagonist of P2X(3) and P2X(2/3) receptors, reduces chronic inflammatory and neuropathic pain in the rat. Proc Natl Acad Sci U S A 2002; 99:17179-17184.
7. Fundytus ME, Osborne MG, Henry JL, et al. Antisense oligonucleotide knockdown of mGluR(1) alleviates hyperalgesia and allodynia associated with chronic inflammation. Pharmacol Biochem Behav 2002; 73:401-410.
8. Lembo PMC, Grazzini E, Groblewski T, et al. Proenkephalin A gene products activate a new family of sensory neuron-specific GPCRs. Nat Neurosci 2002; 5:201-209.
9. Watkins LR, Maier S. Beyond neurons: evidence that immune and glial cells contribute to pathological pain states. Physiol Rev 2002; 82:981-1011. A very comprehensive review of central inflammatory mechanisms and the importance of glial cells and inflammatory mediators.
10. Garcia-Martiez C, Humet M, Planells-Casas R, et al. Attenuation of thermal nociception and hyperalgesia by VR1 blockers. Proc Nat Acad Sci U S A 2002; 99:2374-2379.
11. Story GM, Peier AM, Reeve AJ, et al. ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. Cell 2003; 112:819-829.
12. Barclay J, Patel S, Dorn G, et al. Functional downregulation of P2X(3) receptor subunit in rat sensory neurons reveals a significant role in chronic neuropathic and inflammatory pain. J Neurosci 2002; 22:8139-8147.
13. Nong Y, Huang YQ, Ju W, et al. Glycine binding primes NMDA receptor internalization. Nature 2003; 422:302-307.
14. Gold MS, Weinreich D, Kim C-K, et al. Redistribution of NaV 1.8 in uninjured axons enables neuropathic pain. J Neurosci 2003; 23:156-166.
15. Luo ZD, Calcutt NA, Higuera ES, et al. Injury type-specific calcium channel alpha (2) delta-1 subunit up-regulation in rat neuropathic pain models correlates with antiallodynic effects of gabapentin. J Pharmacol Exp Ther 2002; 303:1199-1205.
16. Chandrasekharan NV, Dai H, Roos KLT, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A 2002; 99:13926-13931.
17. Ji RR, Samad TA, Jin S-X, et al. p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 2002; 36:57-68.
18. Ciruela A, Dixon AK, Bramwell S, et al. Identification of MEK1 as a novel target for the treatment of neuropathic pain. Br J Pharmacol 2003; 138:751-756.
19. Schafers M, Svensson CI, Sommer C, Sorkin LS. Tumor necrosis factor-α induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J Neurosci 2003; 23:2517-2521.